SELLAS Life Sciences Group, Inc. Accretion Expense
SELLAS Life Sciences Group, Inc. (SLS) reported Accretion Expense of $1.42 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. accretion expense for the quarter ending 2017-09-30 was $345.00K, a 39.26% decline year-over-year.
- SELLAS Life Sciences Group, Inc. accretion expense for the quarter ending 2017-06-30 was $428.00K, a 33.64% decline year-over-year.
- SELLAS Life Sciences Group, Inc. accretion expense for the quarter ending 2017-03-31 was $650.00K, a 870.15% increase year-over-year.
- SELLAS Life Sciences Group, Inc. accretion expense for the quarter ending 2016-09-30 was $568.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month |
|---|---|---|---|
| 2017-09-30 | $345.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $773.00K derived: sum of 2 quarters · filed 2017-11-09 | $1.42M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $428.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $1.08M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $650.00K 10-Q · filed 2017-05-10 | ||
| 2016-09-30 | $568.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.21M derived: sum of 2 quarters · filed 2017-11-09 | $1.28M 10-Q · filed 2017-11-09 |
| 2016-06-30 | $645.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $712.00K 10-Q · filed 2017-08-14 | |
| 2016-03-31 | $67.00K 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |